Yiteng pharmaceutical is authorized by syndex pharmaceutical to develop, produce and sell new anticancer drugs exclusively

Recently, Yiteng pharmaceutical, a leading professional pharmaceutical company in China, signed a license agreement with syndex pharmaceutical on the new anticancer drug entinostat Syndex pharmaceutical has been committed to the development of epigenetic therapy drugs for the clinical treatment of refractory cancer This time, syndex pharmaceutical granted Yiteng the exclusive right to develop, produce and sell entinostat in mainland China and several other Asian countries and regions With its strong marketing network and professional experience in China, Yiteng pharmaceutical will develop and promote entinostat Entinostat is one of the main R & D drugs of syndax pharmaceutical According to preliminary clinical trials conducted by syndax pharmaceutical, entinostat has a positive therapeutic effect on breast cancer and lung cancer This cooperation will bring new advantages to drug development and market development, and both sides have expressed their long-term cooperation vision It is reported that Yiteng pharmaceutical will not only pay the license fee of syndax pharmaceutical related to entinostat, but also invest in syndax pharmaceutical "We are looking forward to working closely with syndex pharmaceutical, which will promote the use of entinostat in the treatment of breast cancer, lung cancer and other diseases," said Ni Xin, chairman and CEO of Yiteng pharmaceutical, referring to the cooperation We are committed to bringing cutting-edge and effective medical means to patients in China and even Asia At the same time, we believe that cooperation with syndex pharmaceutical will bring more opportunities and help to cancer patients in our Asian market " It is understood that in addition to the exclusive distribution and production rights of entinstat, Yiteng pharmaceutical will also participate in the phase III clinical trials of entinstat Global Multi Center The two sides will also set up a joint management committee to jointly manage the development, production and sales of products and share all relevant data, so as to achieve better supervision and coordination effect Ms Arlene M Morris, chief executive officer of syndex pharmaceutical, said: "we all see this Agreement as the starting point for our cooperation The financing activities, agreement signing and data sharing for cooperative development represent the important commitments and efforts made by Yiteng pharmaceutical to achieve cooperation The result of the cooperation will bring changes and influence to Chinese patients suffering from advanced or refractory cancer " Since its establishment in 2001, Yiteng pharmaceutical has become a partner of world-famous pharmaceutical companies in China by virtue of its deep understanding of the Chinese local market and professional academic promotion ability, in the form of patent authorization introduction, establishment of joint venture, establishment of strategic alliance, exclusive distribution, etc In 2012, Yiteng pharmaceutical and Casey pharmaceutical established a joint venture company in Hong Kong, Casey Yiteng (Hong Kong) Co., Ltd., which is responsible for the exclusive sale of two key respiratory new drug products under Casey pharmaceutical, so as to promote its wide and rapid access to the Chinese market In 2013, Yiteng pharmaceutical won the exclusive distribution right of thalassar, a patent drug of GlaxoSmithKline for breast cancer treatment, in China The signing of this contract with syndex pharmaceutical is another significant progress of Yiteng pharmaceutical in the implementation of the development strategy of patented pharmaceutical products About Yiteng medicine Founded in 2001, Yiteng pharmaceutical is a professional pharmaceutical company Yiteng pharmaceutical is committed to introducing global high-quality medical products into the Chinese medical market, bringing good news and hope to Chinese patients The company is mainly engaged in drug distribution and promotion, product registration and clinical trial management, focusing on product development and medical promotion in clinical nutrition, anti-tumor treatment, anti infection treatment, respiratory disease treatment and other fields In March 2012, Yiteng pharmaceutical established the eddingpharm (US) Company in the United States, and established a product development team with R & D background in Los Angeles, which is mainly responsible for coordinating and communicating with the world's leading R & D institutions, and seeking the opportunity to introduce new patented drugs in the pre clinical or clinical trial stage into the Chinese market For details, please refer to the official website of Yiteng pharmaceutical: http:// About syndex Pharma Syndax focuses on the use of epigenetic methods to overcome drug resistance in solid tumor treatment The company owns the global patent rights of entinostat Entinostat is an oral, highly selective histone deacetylase (HDAC) inhibitor for the clinical treatment of advanced breast cancer and lung cancer In the treatment of a group of non-small cell lung cancer patients (Encore 401), the combination of entinostat and EGFR-TKI erlotinib also achieved positive and effective results NCI and syndex have reached a cooperative research and development agreement on the development of entinostat, aiming to improve the survival rate of advanced and refractory cancers For details, please refer to the official website of synadax: http:// About entinostat Entinostat is the main candidate product of syndax pharmaceutical It has been studied in 800 cancer patients to observe the objective tumor response of solid tumor and malignant hematopathy Entinostat is a novel oral HDAC inhibitor Because of its obvious safety and effectiveness, it is different from other histone deacetylase (HDAC) inhibitors either as a single drug or in combination with existing targeted therapeutic drugs In normal cells, the enzyme plays a key role in controlling gene expression by changing the structure of chromatin, while in tumor cells, the enzyme will overexpress and lead to reversible resistance based on epigenetics Entinostat can selectively target the HDAC subtype most related to tumor biology, normalize the expression of out of control genes in tumor cells, and restore the sensitivity to other targeted therapeutic drugs Because of its excellent clinical results in breast and lung cancer, entinostat is preparing for a critical phase III clinical trial Entinostat is the first HDAC inhibitor to obtain positive results in phase II clinical randomized controlled trials of breast cancer, and the only HDAC inhibitor developed in the late stage of breast cancer.